Crescent Biopharma, Inc. balance sheet

At the end of fiscal 2025, Crescent Biopharma, Inc. had total assets of $240m, total liabilities of $37.3m and shareholders' equity of $203m. It held $213m in cash against $0 of debt: net cash of $213m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Crescent Biopharma, Inc.: balance sheet, annual
Fiscal year	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2025Dec 2025
Cash and equivalents	17	2	55	47	40	137	90	48	42	213
Receivables	—	—	—	—	—	—	—	—	—	18
Total current assets	—	5	56	47	41	138	91	51	44	237
Total assets	—	5	57	48	42	143	94	52	45	240
Accounts payable	—	1	1	1	2	2	2	1	1	—
Deferred revenue (current)	—	—	—	—	—	—	—	—	—	4
Total current liabilities	—	2	6	8	6	12	12	9	7	36
Long-term debt	—	—	—	—	—	—	—	—	—	0
Total debt	0	0	0	0	0	0	0	0	0	0
Total liabilities	—	2	6	8	7	15	13	9	7	37
Shareholders' equity	13	3	51	40	35	128	82	43	38	203
Net debt (negative = net cash)	−17	−2	−55	−47	−40	−137	−90	−48	−42	−213
Shares outstanding	—	—	19m	19m	23m	49m	52m	54m	64m	28m

US$ millions unless shown otherwise. Fiscal quarters.

Crescent Biopharma, Inc.: balance sheet, quarterly
Quarter	2022 Q2Jun 2022	2022 Q3Sept 2022	2022 Q4Dec 2022	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Receivables	—	—	—	0	—	—	0	0
Total current assets	61	54	51	35	6	154	196	179
Total assets	65	56	52	36	6	157	199	183
Accounts payable	1	1	1	0	0	—	—	—
Deferred revenue (current)	—	—	—	0	—	—	3	3
Total current liabilities	9	8	9	10	3	17	14	19
Long-term debt	—	—	—	37	—	0	—	—
Total debt	—	—	—	37	—	0	—	—
Total liabilities	9	8	9	47	3	18	15	20
Shareholders' equity	56	48	43	−15	−30	139	184	163
Non-controlling interests and other (assets − liabilities − equity)	—	—	—	4	34	—	—	—
Shares outstanding	52m	52m	54m	1m	65m	14m	28m	28m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: CBIO vs LGVN CBIO vs STTK CBIO vs DARE

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Crescent Biopharma, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Crescent Biopharma, Inc.